<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: Additional ", fill: "#708090"},
{source: "3: Additional ", target: "3: uncertainties", fill: "#708090"},
{source: "3: uncertainties", target: "3: presently known", fill: "#708090"},
{source: "3: presently known", target: "3: operations", fill: "#708090"},
{source: "3: Additional ", target: "10: depends on", fill: "#fffacd"},
{source: "10: depends on", target: "10: expense levels", fill: "#fffacd"},
{source: "10: expense levels", target: "10: margin which", fill: "#fffacd"},
{source: "10: margin which", target: "10: influenced by", fill: "#fffacd"},
{source: "10: influenced by", target: "10: development", fill: "#fffacd"},
{source: "10: development", target: "10: manufacturing efficiencies license fees", fill: "#fffacd"},
{source: "10: manufacturing efficiencies license fees", target: "10: license fees", fill: "#fffacd"},
{source: "10: license fees", target: "10: new technology", fill: "#fffacd"},
{source: "10: new technology", target: "10: technology", fill: "#fffacd"},
{source: "10: technology", target: "10: new markets which could", fill: "#fffacd"},
{source: "10: new markets which could", target: "10: pay unanticipated", fill: "#fffacd"},
{source: "10: pay unanticipated", target: "10: connection with", fill: "#fffacd"},
{source: "10: depends on", target: "24: Contents ", fill: "#00416a"},
{source: "24: Contents ", target: "24: researching", fill: "#00416a"},
{source: "24: researching", target: "24: several tests", fill: "#00416a"},
{source: "24: several tests", target: "24: MRSA Many ", fill: "#00416a"},
{source: "24: MRSA Many ", target: "24: factors may affect", fill: "#00416a"},
{source: "24: factors may affect", target: "24: market acceptance", fill: "#00416a"},
{source: "24: market acceptance", target: "24: commercial success", fill: "#00416a"},
{source: "24: commercial success", target: "24: timely development", fill: "#00416a"},
{source: "24: timely development", target: "24: clinical trials", fill: "#00416a"},
{source: "24: clinical trials", target: "24: regulatory", fill: "#00416a"},
{source: "24: regulatory", target: "24: regulatory clearances", fill: "#00416a"},
{source: "24: regulatory clearances", target: "24: tests under development on", fill: "#00416a"},
{source: "24: tests under development on", target: "24: timely basis", fill: "#00416a"},
{source: "24: timely basis", target: "24: market entry", fill: "#00416a"},
{source: "24: market entry", target: "24: various tests", fill: "#00416a"},
{source: "24: various tests", target: "24: GeneXpert ", fill: "#00416a"},
{source: "24: GeneXpert ", target: "24: SmartCycler ", fill: "#00416a"},
{source: "24: SmartCycler ", target: "24: potential customers", fill: "#00416a"},
{source: "24: potential customers", target: "24: advantages", fill: "#00416a"},
{source: "24: advantages", target: "24: economic value", fill: "#00416a"},
{source: "24: economic value", target: "24: tests over competing technologies", fill: "#00416a"},
{source: "24: tests over competing technologies", target: "24: test menu relative", fill: "#00416a"},
{source: "24: test menu relative", target: "24: competitors", fill: "#00416a"},
{source: "24: competitors", target: "24: sales efforts", fill: "#00416a"},
{source: "24: sales efforts", target: "24: publicity concerning", fill: "#00416a"},
{source: "24: Contents ", target: "51: facilities", fill: "#f6c"},
{source: "51: facilities", target: "51: accordance with", fill: "#f6c"},
{source: "51: accordance with", target: "51: requirements international", fill: "#f6c"},
{source: "51: requirements international", target: "51: regulatory requirements", fill: "#f6c"},
{source: "51: regulatory requirements", target: "51: manufacturing", fill: "#f6c"},
{source: "51: manufacturing", target: "51: process could", fill: "#f6c"},
{source: "51: process could", target: "51: terminated which would harm", fill: "#f6c"},
{source: "51: facilities", target: "54: enter into", fill: "#d71868"},
{source: "54: enter into", target: "54: new agreement", fill: "#d71868"},
{source: "54: new agreement", target: "54: industry markets", fill: "#d71868"},
{source: "54: enter into", target: "56: Furthermore ", fill: "#0abab5"},
{source: "56: Furthermore ", target: "56: manufacture", fill: "#0abab5"},
{source: "56: manufacture", target: "56: instruments", fill: "#0abab5"},
{source: "56: Furthermore ", target: "60: Furthermore ", fill: "#f96"},
{source: "60: Furthermore ", target: "60: competitors", fill: "#f96"},
{source: "60: competitors", target: "60: technologies", fill: "#f96"},
{source: "60: technologies", target: "60: which may put us at", fill: "#f96"},
{source: "60: which may put us at", target: "60: competitive", fill: "#f96"},
{source: "60: competitive", target: "60: disadvantage", fill: "#f96"},
{source: "60: disadvantage", target: "60: certain circumstances", fill: "#f96"},
{source: "60: certain circumstances", target: "60: could adversely affect", fill: "#f96"},
{source: "60: Furthermore ", target: "182: difficulties", fill: "#fe6f5e"},
{source: "182: difficulties", target: "182: special costs", fill: "#fe6f5e"},
{source: "182: special costs", target: "182: compliance with multiple conflicting", fill: "#fe6f5e"},
{source: "182: compliance with multiple conflicting", target: "182: governmental laws", fill: "#fe6f5e"},
{source: "182: governmental laws", target: "182: regulations", fill: "#fe6f5e"},
{source: "182: regulations", target: "182: practices favoring local competitors", fill: "#fe6f5e"},
{source: "182: practices favoring local competitors", target: "182: currency risks", fill: "#fe6f5e"},
{source: "182: currency risks", target: "182: potential difficulty", fill: "#fe6f5e"},
{source: "182: potential difficulty", target: "182: collecting accounts receivable", fill: "#fe6f5e"},
{source: "182: collecting accounts receivable", target: "182: export restrictions", fill: "#fe6f5e"},
{source: "182: export restrictions", target: "182: difficulties staffing", fill: "#fe6f5e"},
{source: "182: difficulties staffing", target: "182: managing foreign operations", fill: "#fe6f5e"},
{source: "182: managing foreign operations", target: "182: enforcing intellectual property rights", fill: "#fe6f5e"},
{source: "182: enforcing intellectual property rights", target: "182: fluctuations", fill: "#fe6f5e"},
{source: "182: fluctuations", target: "182: conduct international operations", fill: "#fe6f5e"},
{source: "182: conduct international operations", target: "182: travel abroad", fill: "#fe6f5e"},
{source: "182: travel abroad", target: "182: promote international distribution", fill: "#fe6f5e"},
{source: "182: promote international distribution", target: "182: global economic conditions", fill: "#fe6f5e"},
{source: "182: global economic conditions", target: "182: multiple conflicting tax laws", fill: "#fe6f5e"},
{source: "182: multiple conflicting tax laws", target: "182: economic instability", fill: "#fe6f5e"},
{source: "182: difficulties", target: "START_HERE", fill: "#fe6f5e"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Formally complain</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Met_Operations">Met Operations</a></td>
      <td>Met Operations, also known as Met Ops, is one of the four business groups which forms the Metropolitan Police Service. It was created during the 2018-19 restructuring of the service, amalgamating many of its functions from the Operations side of the Specialist Crime &amp; Operations Directorate formed in 2012, with the Specialist Crime side of that Directorate placed under the new Frontline Policing Directorate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_royale">Manufacture royale</a></td>
      <td>Manufacture Royale is a Swiss luxury watch brand. Founded in the eighteenth century, the brand was revived in 2010.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Agilent_Technologies">Agilent Technologies</a></td>
      <td>Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CEPHEID      ITEM 1A  RISK FACTORS             You <font color="blue">should carefully</font> consider the risks and <font color="blue"><font color="blue">uncertainties</font> described</font>     below, <font color="blue">together with</font> all of the other information included in this report,     in considering our business and prospects</td>
    </tr>
    <tr>
      <td>The risks and <font color="blue">uncertainties</font>     described below are not the <font color="blue">only ones facing</font> Cepheid</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and     <font color="blue">uncertainties</font> not <font color="blue">presently known</font> to us or that we currently deem immaterial     also  may impair our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The occurrence of any of the     <font color="blue">following risks <font color="blue">could harm</font></font> our business, <font color="blue">financial condition</font> or results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have incurred operating losses in <font color="blue">each year since</font> our inception and     expect to have negative cash flow from <font color="blue">operations</font> through at least the end     of 2006</td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, we     had an <font color="blue">accumulated deficit</font> of approximately dlra107dtta5 million</td>
    </tr>
    <tr>
      <td>Our ability to     <font color="blue">become profitable <font color="blue">will depend on</font></font> our ability to increase our revenues, which     is subject to a number of factors including our ability to successfully     penetrate  the <font color="blue">clinical market</font>, our ability to <font color="blue">successfully market</font> the     <font color="blue">GeneXpert </font>system and develop <font color="blue">effective</font> <font color="blue">GeneXpert </font>tests, the extent of our     <font color="blue">participation</font> in the USPS BDS program and the operating <font color="blue">parameters</font> of the     BDS program, which will affect the rate of our <font color="blue">consumable products sold</font>, the     success  of  our  other <font color="blue"><font color="blue">collaborative</font> programs</font>, our ability to compete     <font color="blue">effective</font>ly against current and future <font color="blue">competitors</font>, global economic and     <font color="blue">political conditions</font> and the impact of the <font color="blue">new accounting</font> for share-based     payments  <font color="blue">such as stock options</font></td>
    </tr>
    <tr>
      <td>Our ability to become profitable also     <font color="blue">depends on</font> our <font color="blue">expense levels</font> and product gross margin, which are also     <font color="blue">influenced by</font> a number of factors, including the resources we devote to     developing  and supporting our products, the continued progress of our     research and <font color="blue">development</font> of <font color="blue">potential products</font>, our ability to improve     <font color="blue">manufacturing</font> efficiencies, <font color="blue">license fees</font> or royalties we may be required to     pay, and the potential need to acquire licenses to <font color="blue">new <font color="blue">technology</font></font> or to use     our <font color="blue">technology</font> in new markets, <font color="blue">which could</font> require us to <font color="blue">pay unanticipated</font>     <font color="blue">license fees</font> and royalties in <font color="blue">connection with</font> these licenses</td>
    </tr>
    <tr>
      <td>Our expansion     <font color="blue">efforts may prove</font> more <font color="blue">expensive than</font> we currently anticipate, and we may     not succeed in increasing our revenues to <font color="blue">offset higher expenses</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>expenses, among other things, may cause our net income and working capital     to decrease</td>
    </tr>
    <tr>
      <td>If we fail to grow our revenue and manage our expenses and     improve our product gross margin, we may never achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If we     fail to do so, the <font color="blue">market price</font> of our <font color="blue"><font color="blue">common stock</font> will likely decline</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">participation</font> in the <font color="blue">USPS Biohazard Detection System </font>program and other     similar <font color="blue">programs may</font> not result in <font color="blue">predictable contracts</font> or revenues</td>
    </tr>
    <tr>
      <td>Our <font color="blue">participation</font> in the USPS BDS program or any similar <font color="blue">government</font>     programs  involves  <font color="blue">significant</font>  <font color="blue">uncertainties</font> related to <font color="blue">government</font>al     decision-making and timing of <font color="blue">deployment</font>, and is <font color="blue">highly sensitive</font> to changes     in national and <font color="blue">international priorities</font> and budgets</td>
    </tr>
    <tr>
      <td>The <font color="blue">world geopolitical</font>     climate in the wake of the <font color="blue">September </font>11, 2001 terrorist attacks has created     substantial <font color="blue">public interest</font> in the BDS However, <font color="blue">budgetary pressures may</font>     result in <font color="blue">reduced allocations</font> to <font color="blue">government</font> agencies such as the USPS,     <font color="blue">sometimes without advanced</font> notice</td>
    </tr>
    <tr>
      <td>We cannot be certain that <font color="blue">actual funding</font>     and operating <font color="blue">parameters</font>, or product purchases, will occur <font color="blue">at currently</font>     expected levels or in the currently expected timeframe</td>
    </tr>
    <tr>
      <td>In this and any     similar future programs, there may be <font color="blue">no obligation on</font> the part of the     <font color="blue">eventual customer</font> to buy a minimum number of units or tests, so, <font color="blue">even though</font>     we have <font color="blue">been awarded</font> a <font color="blue">production contract</font>, we may be subject to future     <font color="blue">spending patterns</font> and <font color="blue">budgetary cycles</font></td>
    </tr>
    <tr>
      <td>Furthermore, if we <font color="blue">participate</font> in     any other <font color="blue"><font color="blue">collaboration</font>s bidding</font> for <font color="blue">government</font> contracts, the bidding and     <font color="blue">evaluation <font color="blue">process could</font></font> be lengthy and involve <font color="blue">significant</font> expense, and may     not result in a contract or a <font color="blue">contract with</font> acceptable terms</td>
    </tr>
    <tr>
      <td>Accordingly,     our <font color="blue">participation</font> in the USPS BDS program and other similar programs is     subject  to  a number of risks and <font color="blue">uncertainties</font> and may not yield the     expected revenues</td>
    </tr>
    <tr>
      <td>If we <font color="blue"><font color="blue">cannot successfully</font> <font color="blue">commercialize</font></font> our products, our business could be     harmed</td>
    </tr>
    <tr>
      <td>If our tests for use on the <font color="blue">SmartCycler </font>and <font color="blue">GeneXpert </font>platforms do not     <font color="blue">gain <font color="blue">market <font color="blue">acceptance</font></font></font>, we will be unable to generate <font color="blue">significant</font> sales,     <font color="blue">which will prevent us from</font> achieving <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We are in the                                         17       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font>process of <font color="blue">researching</font> and developing <font color="blue">several tests</font>, including <font color="blue">MRSA Many     </font><font color="blue"><font color="blue">factors may</font> affect</font> the <font color="blue">market <font color="blue">acceptance</font></font> and <font color="blue">commercial success</font> of our     products, including:         •  timely <font color="blue">development</font> of a menu of tests and reagents;         •  the results of <font color="blue">clinical trials</font> needed to support any <font color="blue">regulatory</font>     approvals of our tests;         •  our ability to obtain requisite FDA or other <font color="blue">regulatory</font> <font color="blue">clearances</font> or     approvals for our tests under <font color="blue">development</font> on a <font color="blue">timely basis</font>;         •  demand for the tests and reagents we are able to introduce;         •  the timing of <font color="blue">market entry</font> for <font color="blue">various tests</font> for the <font color="blue">GeneXpert </font>and the     <font color="blue">SmartCycler </font>systems;         •  our ability to convince our <font color="blue">potential customers</font> of the <font color="blue">advantages</font> and     <font color="blue">economic value</font> of our systems and <font color="blue">tests over competing <font color="blue">technologies</font></font> and     products;         •  the breadth of our <font color="blue">test menu relative</font> to <font color="blue">competitors</font>;         •  the extent and success of our marketing and <font color="blue">sales efforts</font>; and         •  <font color="blue">publicity concerning</font> our systems and tests</td>
    </tr>
    <tr>
      <td>In particular, we believe that the success of our business will depend     in large part on our ability to <font color="blue">commercialize</font> our products for the clinical     <font color="blue">diagnostic</font>  market</td>
    </tr>
    <tr>
      <td>Our <font color="blue">current reliance on <font color="blue">revenues from</font></font> the <font color="blue">USPS BDS     </font>program  has  resulted in substantial <font color="blue">revenue concentrations</font> in recent     periods</td>
    </tr>
    <tr>
      <td>We believe that successfully building our business in the clinical     market is critical to our long-term goals and success</td>
    </tr>
    <tr>
      <td>We have limited     experience  operating in the <font color="blue">clinical market</font> and, as a result, we have     limited ability to <font color="blue">forecast future demand</font> for our products in this market</td>
    </tr>
    <tr>
      <td>In  addition, we have committed substantial funds to licenses that are     required for us to enter the <font color="blue">clinical market</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot successfully</font>     penetrate the <font color="blue">clinical market</font> to exploit these licenses, ongoing payments     that we have agreed to make under them could <font color="blue">significant</font>ly harm our business     and operating results in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> approval process is expensive, time-consuming, and uncertain     and <font color="blue">may prevent us from</font> obtaining required approvals for the     <font color="blue">commercialization</font> of some of our products</td>
    </tr>
    <tr>
      <td>In the <font color="blue">clinical market</font>, our products may <font color="blue">generally</font> be regulated as     medical devices by the FDA and comparable agencies of other countries</td>
    </tr>
    <tr>
      <td>In     particular, FDA <font color="blue">regulations</font> govern <font color="blue">activities</font> such as product <font color="blue">development</font>,     product testing, product labeling, product storage, premarket clearance or     approval, <font color="blue">manufacturing</font>, advertising, promotion, product sales, reporting of     <font color="blue">certain product failures</font> and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>The 510(k) clearance     <font color="blue">process usually</font> takes from three to six months from submission, but can take     longer</td>
    </tr>
    <tr>
      <td>The <font color="blue">premarket approval process</font> is much more costly, lengthy, and     uncertain  and  <font color="blue">generally</font>  takes  from one to two years or <font color="blue">longer from</font>     submission</td>
    </tr>
    <tr>
      <td>Clinical trials are <font color="blue">generally</font> required to <font color="blue">support both</font> PMA and     510(k) <font color="blue">submissions</font></td>
    </tr>
    <tr>
      <td>Certain of our products for use on our <font color="blue">SmartCycler </font>and     <font color="blue">GeneXpert </font>systems, when used for clinical purposes, may require premarket     approval and all such tests will most likely, at a minimum, require 510(k)     clearance</td>
    </tr>
    <tr>
      <td>We are in the process of conducting <font color="blue">clinical trials</font> for several     of our <font color="blue">proposed test products</font> and are planning <font color="blue">clinical trials</font> for other     <font color="blue">proposed products</font></td>
    </tr>
    <tr>
      <td>Clinical trials are expensive and time-consuming</td>
    </tr>
    <tr>
      <td>In     addition, the <font color="blue">commencement</font> or <font color="blue">completion</font> of any <font color="blue">clinical trials</font> may be     delayed or halted for any number of reasons, including <font color="blue">product performance</font>,     changes  in  <font color="blue">intended use</font>, changes in <font color="blue">medical practice</font> and <font color="blue">issues with</font>     evaluator <font color="blue">Institutional Review Boards</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> the applicable <font color="blue">requirements</font> can result in,     among other things, warning letters, <font color="blue">administrative</font> or <font color="blue">judicially</font> imposed     sanctions  such  as <font color="blue">injunctions</font>, civil penalties, recall or seizure of     products,  total or partial suspension of production, refusal to grant     premarket  clearance  or premarket approval for devices, withdrawal of     marketing <font color="blue">clearances</font> or approvals, or criminal <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>To date, only     the <font color="blue">GBS and MRSA </font>tests developed by Infectio Diagnostics, Inc</td>
    </tr>
    <tr>
      <td>(IDI) for use     on the <font color="blue">SmartCycler </font>have received FDA clearance</td>
    </tr>
    <tr>
      <td>Approval or clearance from     the  FDA  or any other <font color="blue">government</font>al body has not <font color="blue">been sought</font> for other     products for the <font color="blue">SmartCycler </font>or GeneXpert</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>were to <font color="blue">disagree with</font>     our <font color="blue">regulatory</font> assessment and                                         18       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>conclude that approval or clearance is <font color="blue">necessary</font> to market the products, we     could  be  forced to <font color="blue">cease marketing</font> the products and <font color="blue">seek approval</font> or     clearance</td>
    </tr>
    <tr>
      <td>With regard to those <font color="blue">future products</font> for which we will seek     510(k) clearance or <font color="blue">premarket approval from</font> the FDA, any failure or material     delay to obtain such clearance or approval <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>In     addition, it is possible that the current <font color="blue">regulatory</font> framework could change     or  <font color="blue"><font color="blue">additional</font> <font color="blue">regulations</font> could</font> arise at any <font color="blue">stage during</font> our product     <font color="blue">development</font> or marketing, which may <font color="blue">adversely</font> affect our ability to obtain     or maintain approval of our products and <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font>, where we assemble and produce the     <font color="blue">SmartCycler </font>system and the <font color="blue">GeneXpert </font>system, <font color="blue">cartridges</font> and reagents, are     subject to periodic <font color="blue">regulatory</font> inspections by the FDA and other federal and     state <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>For example, these <font color="blue">facilities</font> are subject to     Quality  System Regulations (QSR) of the FDA and are subject to annual     inspection and licensing by <font color="blue">the State of California</font></td>
    </tr>
    <tr>
      <td>If we fail to maintain     these <font color="blue">facilities</font> in <font color="blue">accordance with</font> the QSR <font color="blue">requirements</font>, international     quality  standards or other <font color="blue">regulatory</font> <font color="blue">requirements</font>, our <font color="blue">manufacturing</font>     <font color="blue">process could</font> be suspended or terminated, which would harm our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on licenses</font> of key <font color="blue">technology</font> from <font color="blue">third parties</font> and will require     <font color="blue"><font color="blue">additional</font> licenses</font> for many of our <font color="blue">new product candidates</font></td>
    </tr>
    <tr>
      <td>We  rely on third-party licenses to be able to sell many of our     products, and we <font color="blue">could lose</font> any of our third-party licenses for a number of     reasons, including, for example, early <font color="blue">termination</font>s of <font color="blue">such <font color="blue">agreement</font>s due</font>     to breaches or alleged <font color="blue">breaches by either party</font> to the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>If we are     unable to <font color="blue">enter into</font> a new <font color="blue">agreement</font> for licensed <font color="blue">technologies</font>, either on     terms that are acceptable to us or at all, we may be unable to sell some of     our products or access some geographic or <font color="blue">industry markets</font></td>
    </tr>
    <tr>
      <td>We also need to     introduce <font color="blue">new products</font> and product features in order to market our products     to a <font color="blue">broader customer base</font> and grow our revenues, and many <font color="blue">new products</font> and     product features could require us to obtain <font color="blue"><font color="blue">additional</font> licenses</font> and pay     <font color="blue">additional</font> <font color="blue">license fees</font> and royalties</td>
    </tr>
    <tr>
      <td>Furthermore, for some markets, we     intend to <font color="blue">manufacture</font> reagents and tests for use on our <font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>We     believe that <font color="blue">manufacturing</font> reagents and developing tests for our <font color="blue">instruments</font>     is  important  to  our business and growth prospects, but will require     <font color="blue"><font color="blue">additional</font> licenses</font>, which may not be <font color="blue">available <font color="blue">on <font color="blue">commercially</font></font> reasonable</font>     terms or at all</td>
    </tr>
    <tr>
      <td>Our ability to develop, <font color="blue">manufacture</font> and <font color="blue">sell products</font>, and     our strategic plans and growth, could be impaired if we are unable to obtain     these licenses or if these licenses are terminated or expire and cannot be     renewed</td>
    </tr>
    <tr>
      <td>We may not be able to obtain or <font color="blue">renew licenses</font> for a <font color="blue">given product</font>     or product feature, or for some reagents, <font color="blue">on <font color="blue">commercially</font></font> reasonable terms,     if at all</td>
    </tr>
    <tr>
      <td>Furthermore, some of our <font color="blue">competitors</font> have rights to <font color="blue">technologies</font>     and  reagents  that  we do not have, <font color="blue">which may put us at</font> a <font color="blue">competitive</font>     <font color="blue">disadvantage</font>  in  <font color="blue">certain circumstances</font> and <font color="blue">could <font color="blue">adversely</font> affect</font> our     performance</td>
    </tr>
    <tr>
      <td>If we acquire companies, products or <font color="blue">technologies</font>, we <font color="blue">may face risks</font>     <font color="blue">associated with</font> those <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>If we are <font color="blue">presented with appropriate opportunities</font>, we intend to     acquire or make other <font color="blue"><font color="blue">investment</font>s</font> in <font color="blue">complementary</font> companies, products or     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We may not realize the anticipated benefit of any <font color="blue">acquisition</font>     or <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>If we acquire companies or <font color="blue">technologies</font>, we <font color="blue">will likely face</font>     risks,  <font color="blue">uncertainties</font>  and disruptions <font color="blue">associated with</font> the <font color="blue">integration</font>     process, including <font color="blue"><font color="blue">difficult</font>ies</font> in the <font color="blue">integration</font> of these <font color="blue">operations</font> and     services of an acquired company, <font color="blue">integration</font> of acquired <font color="blue">technology</font> with our     products,  diversion of our <font color="blue">management</font>’s attention from other business     concerns, the <font color="blue">potential loss</font> of <font color="blue">key employees</font> or customers of the acquired     <font color="blue">businesses</font>  and  <font color="blue">impairment</font>  charges if future <font color="blue"><font color="blue">acquisition</font>s</font> are not as     <font color="blue">successful as</font> we <font color="blue">originally</font> anticipate</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">successfully integrate</font>     other companies, products or <font color="blue">technologies</font> that we may acquire, our business     could be harmed</td>
    </tr>
    <tr>
      <td>Furthermore, we may have to incur debt or <font color="blue">issue equity</font>     securities to pay for any <font color="blue">additional</font> future <font color="blue"><font color="blue">acquisition</font>s</font> or <font color="blue"><font color="blue">investment</font>s</font>, the     issuance  of  <font color="blue">which could</font> be dilutive to our <font color="blue">existing <font color="blue">shareholders</font></font></td>
    </tr>
    <tr>
      <td>In     addition, our operating results may suffer because of <font color="blue">acquisition</font>-related     costs or <font color="blue">amortization expenses</font> or charges relating to acquired intangible     assets</td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font><font color="blue">Concerns </font>about other national and international crises may increase public     interest in <font color="blue">products such as ours</font></td>
    </tr>
    <tr>
      <td><font color="blue">Concerns </font><font color="blue">about recent</font> perceived international crises, such as the     spread of <font color="blue">severe acute respiratory syndrome</font> (SARS), <font color="blue">avian influenza</font>, or bird     flu,  or West Nile viruses may increase <font color="blue">public interest</font> in products or     <font color="blue">technologies</font> such as ours, even if there are <font color="blue">no <font color="blue">commercially</font> available</font>     products for <font color="blue">such <font color="blue">applications</font></font></td>
    </tr>
    <tr>
      <td>This <font color="blue">increased interest could affect</font> the     <font color="blue">market price</font> of our <font color="blue">common stock</font>, despite the fact that we have not achieved     any material <font color="blue">revenues from</font> these <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>In addition, public concern     over these <font color="blue">issues could wane over</font> time, <font color="blue">which could</font> result in a decline in     the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any products     that we may develop to address any <font color="blue">such concerns will</font> result in any material     revenues to us</td>
    </tr>
    <tr>
      <td>We expect that our operating results <font color="blue">will fluctuate</font> <font color="blue">significant</font>ly, and any     failure to <font color="blue">meet financial <font color="blue">expectations</font> may</font> result in a decline in our stock     price</td>
    </tr>
    <tr>
      <td>We expect that our quarterly operating results <font color="blue">will fluctuate</font> in the     future as a result of many factors, such as those <font color="blue">described elsewhere</font> in     this section, many of which are beyond our control</td>
    </tr>
    <tr>
      <td>Because our revenue and     operating results are <font color="blue">difficult</font> to predict, we believe that period-to-period     <font color="blue">comparisons</font> of our results of <font color="blue">operations</font> are not a good indicator of our     <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>Our operating results may be <font color="blue">affected by</font> the <font color="blue">inability</font>     of  some  of  our customers to consummate anticipated purchases of our     products, whether due to changes in <font color="blue">internal priorities</font> or, in the case of     <font color="blue">government</font>al  customers,  <font color="blue">problems with</font> the <font color="blue">appropriations process</font> and     <font color="blue">variability</font>  and timing of orders, or <font color="blue">manufacturing</font> inefficiencies</td>
    </tr>
    <tr>
      <td>If     revenue  declines  in a quarter, whether due to a delay in recognizing     expected revenue, unexpected costs or otherwise, our results of <font color="blue">operations</font>     will  be  harmed because many of our expenses are <font color="blue">relatively</font> fixed</td>
    </tr>
    <tr>
      <td>In     particular, research and <font color="blue">development</font> and selling, general and <font color="blue">administrative</font>     expenses are not <font color="blue">significant</font>ly <font color="blue">affected by</font> variations in revenue</td>
    </tr>
    <tr>
      <td>If our     quarterly operating results fail to meet or exceed the <font color="blue">expectations</font> of     <font color="blue">securities analysts</font> or investors, our <font color="blue">stock price could drop suddenly</font> and     <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">manufacture</font> our products in <font color="blue">sufficient quantities</font> and in     a <font color="blue">timely manner</font>, our operating results will be harmed and our ability to     <font color="blue">generate revenue could</font> be diminished</td>
    </tr>
    <tr>
      <td>Our revenues and other operating results will depend in large part on     our  ability  to  <font color="blue">manufacture</font>  and assemble our products in sufficient     quantities and in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>Any interruptions we experience in the     <font color="blue">manufacturing</font>  or  shipping of our <font color="blue"><font color="blue">products could</font> delay</font> our ability to     recognize revenues in a <font color="blue">particular quarter</font></td>
    </tr>
    <tr>
      <td>We have limited experience in     <font color="blue">manufacturing</font> large volumes of products and <font color="blue">manufacturing</font> problems can and     do arise or we may be unable to adequately scale-up <font color="blue">manufacturing</font> in a     timely  manner  or on a <font color="blue"><font color="blue">commercially</font> reasonable basis</font> if we experience     <font color="blue">increased demand</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">react quickly enough</font> to <font color="blue">ship products</font> and     recognize  anticipated  revenues  for  a <font color="blue">given period</font> if we experience     <font color="blue">significant</font>  delays  in the <font color="blue">manufacturing</font> process</td>
    </tr>
    <tr>
      <td>If we are unable to     <font color="blue">manufacture</font> our <font color="blue">products consistently</font> and on a <font color="blue">timely basis</font>, our revenues     <font color="blue">from product sales</font>, gross margins and our other operating results will be     <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">certain single source suppliers fail</font> to deliver <font color="blue">key product <font color="blue">components</font></font> in     a <font color="blue">timely manner</font>, our <font color="blue">manufacturing</font> ability would be impaired and our product     <font color="blue">sales <font color="blue">could suffer</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on certain single source suppliers</font> that <font color="blue">supply <font color="blue">components</font></font>     used in the <font color="blue">manufacture</font> of the <font color="blue">SmartCycler </font>system, the <font color="blue">GeneXpert </font>modules and     system,  and  our <font color="blue">disposable reaction tubes</font> and <font color="blue">cartridges</font></td>
    </tr>
    <tr>
      <td>If we need     <font color="blue">alternative sources</font> for key component parts for any reason, these component     parts may not be <font color="blue">immediately available</font> to us</td>
    </tr>
    <tr>
      <td>If <font color="blue">alternative suppliers</font> are     not <font color="blue">immediately available</font>, we will have to identify and <font color="blue">qualify alternative</font>     suppliers, and production of these <font color="blue"><font color="blue">components</font> may</font> be delayed</td>
    </tr>
    <tr>
      <td>We may not be     able to find an <font color="blue">adequate alternative supplier</font> in a reasonable time period,     or  <font color="blue">on <font color="blue">commercially</font></font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td><font color="blue">Shipments </font>of affected     products have been limited or delayed as a result of such problems in the     past, and similar <font color="blue">problems could</font> occur in the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to     obtain our <font color="blue">key source supplies</font> for the <font color="blue">manufacture</font>                                         20       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font>of our products may require us to delay shipments of products, harm customer     <font color="blue"><font color="blue">relationship</font>s</font> or force us to curtail or cease <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If certain of our <font color="blue">products fail</font> to obtain an <font color="blue">adequate level</font> of <font color="blue">reimbursement</font>     from third-party payers, our ability to <font color="blue">sell products</font> in the <font color="blue">clinical market</font>     would be harmed</td>
    </tr>
    <tr>
      <td>Our ability to sell our products in the <font color="blue">clinical market</font> will depend in     part on the extent to which <font color="blue">reimbursement</font> for <font color="blue">tests using</font> our <font color="blue">products will</font>     be <font color="blue">available from</font>:         •  <font color="blue">government</font> health care programs and <font color="blue">health administration <font color="blue">authorities</font></font>;         •  <font color="blue">private health coverage insurers</font>;         •  <font color="blue">managed care <font color="blue">organizations</font></font>; and         •  other <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>There are efforts by <font color="blue">government</font>al and third-party payers to contain or     reduce  the  costs of <font color="blue">health care through various</font> means</td>
    </tr>
    <tr>
      <td>Additionally,     third-party  payers  are <font color="blue">increasingly challenging</font> the price of medical     products and services</td>
    </tr>
    <tr>
      <td>If purchasers or users of our products are not able     to obtain adequate <font color="blue">reimbursement</font> for the cost of using our products, they     may forego or reduce their use</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">uncertainty</font> exists as to the     <font color="blue">reimbursement</font> status of <font color="blue">newly approved health care products</font> and whether     adequate third-party coverage will be available</td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> and potential <font color="blue">competitors</font> develop superior products and     <font color="blue">technologies</font>, our <font color="blue">competitive</font> position and results of <font color="blue">operations</font> would     suffer</td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense competition from</font> a number of companies that offer     products in our <font color="blue">target markets</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">competitors</font> include:         •  companies developing and <font color="blue">marketing sequence <font color="blue">detection</font> systems</font> for     <font color="blue">industrial research products</font>;          •  <font color="blue">healthcare companies</font> that <font color="blue">manufacture</font> laboratory-based tests and     <font color="blue">analyzers</font>;         •  <font color="blue">diagnostic</font> companies; and         •  companies developing or offering biothreat <font color="blue">detection</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Several  </font>companies  provide  <font color="blue">instruments</font>  and  reagents for DNA     <font color="blue">amplification</font> or <font color="blue">detection</font></td>
    </tr>
    <tr>
      <td>Applied Biosystems, Roche, Bio-Rad Laboratories     and   <font color="blue">Stratagene   </font>sell  systems  <font color="blue">integrating</font>  DNA  <font color="blue">amplification</font>  and     <font color="blue">detection</font> (sequence <font color="blue">detection</font> systems) to the <font color="blue">commercial market</font></td>
    </tr>
    <tr>
      <td>Idaho     Technologies sells sequence <font color="blue">detection</font> systems to the <font color="blue">military market</font></td>
    </tr>
    <tr>
      <td>Roche,     Abbott Laboratories and GenProbe sell large sequence <font color="blue">detection</font> systems, some     <font color="blue">with separate robotic batch</font> DNA <font color="blue">purification systems</font> and <font color="blue">sell reagents</font> to     the <font color="blue">clinical market</font></td>
    </tr>
    <tr>
      <td>Other companies, including Becton, Dickson and Company,     Bayer and <font color="blue">bioMerieux</font>, offer molecular tests</td>
    </tr>
    <tr>
      <td>If our products do not perform as expected, or the <font color="blue">re<font color="blue">liability</font></font> of the     <font color="blue">technology</font> on which our products are based is questioned, we could     experience <font color="blue">lost revenue</font>, delayed or reduced <font color="blue">market <font color="blue">acceptance</font></font> of our     products, increased costs and damage to our reputation</td>
    </tr>
    <tr>
      <td>Our success <font color="blue">depends on</font> the market’s confidence that we can provide     reliable, high-quality molecular test systems</td>
    </tr>
    <tr>
      <td>We believe that customers in     the industrial, biothreat and <font color="blue">clinical market</font>s are likely to be <font color="blue">particularly</font>     sensitive to <font color="blue">product defects</font> and errors</td>
    </tr>
    <tr>
      <td>Our reputation and the <font color="blue">public image</font>     of our products or <font color="blue">technologies</font> may be impaired if our <font color="blue">products fail</font> to     perform as expected; or our products are perceived as <font color="blue">difficult</font> to use</td>
    </tr>
    <tr>
      <td>Despite testing, defects or <font color="blue">errors could</font> occur in our products or     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>For example, in July 2005, we <font color="blue">notified customers</font> of a software     bug in <font color="blue">connection with</font> the <font color="blue">diagnostic</font> software used in <font color="blue">conjunction with</font> our     <font color="blue">SmartCycler </font>system and <font color="blue">provided replacement software</font> to eliminate this bug</td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">with respect</font> to the BDS program, our products are <font color="blue"><font color="blue">incorporate</font>d</font>     into  <font color="blue">larger systems</font> that are built and delivered by others; we cannot     control many aspects of the <font color="blue">final product</font></td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font>      In the future, if we experience a material defect or error, this could     result in loss or delay of revenues, delayed <font color="blue">market <font color="blue">acceptance</font></font>, damaged     reputation, diversion of <font color="blue">development</font> resources, legal claims, increased     insurance costs or <font color="blue">increased service</font> and <font color="blue">warranty costs</font>, any of <font color="blue">which could</font>     harm our business</td>
    </tr>
    <tr>
      <td>Any failure in the overall BDS, even if it is unrelated     to our products, <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>Even after any <font color="blue">underlying concerns</font>     or problems are resolved, any <font color="blue">widespread concerns</font> regarding our <font color="blue">technology</font>     or any <font color="blue">manufacturing</font> defects or <font color="blue">performance errors</font> in our <font color="blue">products could</font>     result in <font color="blue">lost revenue</font>, delayed <font color="blue">market <font color="blue">acceptance</font></font>, damaged reputation,     <font color="blue">increased service</font> and <font color="blue">warranty costs</font>, and claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">product <font color="blue">liability</font></font> lawsuits are successfully brought <font color="blue">against us</font>, we may     <font color="blue">face reduced demand</font> for our product and incur <font color="blue">significant</font> liabilities</td>
    </tr>
    <tr>
      <td>We face an inherent risk of exposure to <font color="blue">product <font color="blue">liability</font></font> claims if     our  <font color="blue">technologies</font> or systems are alleged to have caused harm or do not     perform in <font color="blue">accordance with</font> <font color="blue">specifications</font>, in part because our products are     used for sensitive <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that we would be able     to <font color="blue">successfully defend</font> any <font color="blue">product <font color="blue">liability</font></font> lawsuit brought <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of merit or eventual outcome, <font color="blue">product <font color="blue">liability</font></font> claims may result     in:         •  decreased demand for our products;         •  injury to our reputation;         •  costs of related <font color="blue">litigation</font>; and         •  substantial monetary awards to plaintiffs</td>
    </tr>
    <tr>
      <td>If we become the subject of a successful <font color="blue">product <font color="blue">liability</font></font> lawsuit, we     <font color="blue">could incur</font> substantial liabilities, which <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>We rely on <font color="blue"><font color="blue">relationship</font>s</font> with <font color="blue">collaborative</font> partners and other <font color="blue">third parties</font>     for <font color="blue">development</font>, supply and marketing of products and <font color="blue">potential products</font>,     and <font color="blue">such <font color="blue">collaborative</font> partners</font> or other <font color="blue">third parties</font> could fail to perform     <font color="blue">sufficiently</font></td>
    </tr>
    <tr>
      <td>We believe that our success in <font color="blue">penetrating</font> our <font color="blue">target markets</font> depends     in part on our ability to develop and maintain <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationship</font>s</font>     with other companies</td>
    </tr>
    <tr>
      <td>Relying on <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationship</font>s</font> is risky to our     <font color="blue">future success</font> because, among other things:         •  our <font color="blue"><font color="blue">collaborative</font> partners may</font> not <font color="blue">devote sufficient resources</font> to the     success of our <font color="blue">collaboration</font>;          •   our  <font color="blue"><font color="blue">collaborative</font> partners may</font> not obtain <font color="blue">regulatory</font> approvals     <font color="blue">necessary</font> to continue the <font color="blue">collaboration</font>s in a <font color="blue">timely manner</font>;         •  our <font color="blue"><font color="blue">collaborative</font> partners may</font> be acquired by another company and     decide to terminate our <font color="blue"><font color="blue">collaborative</font> partnership</font> or <font color="blue">become insolvent</font>;         •  our <font color="blue"><font color="blue">collaborative</font> partners may</font> develop <font color="blue">technologies</font> or <font color="blue">components</font>     <font color="blue">competitive</font> with our products;          •   <font color="blue">components</font>  developed  by  <font color="blue">collaborators</font>  could  fail  to  meet     <font color="blue">specifications</font>,  possibly  causing  us  to <font color="blue">lose potential</font> projects and     <font color="blue">subjecting us</font> to <font color="blue">liability</font>;         •  dis<font color="blue">agreement</font>s with <font color="blue">collaborators</font> could result in the <font color="blue">termination</font> of the     <font color="blue">relationship</font> or <font color="blue">litigation</font>;         •  <font color="blue">collaborators</font> may not have <font color="blue">sufficient capital resources</font>;         •  <font color="blue">collaborators</font> may pursue tests or other products that will not generate     <font color="blue">significant</font>  volume  for  us, but may consume <font color="blue">significant</font> research and     <font color="blue">development</font> and <font color="blue">manufacturing</font> resources;          •   our  existing <font color="blue">collaboration</font>s may preclude us from entering into     <font color="blue"><font color="blue">additional</font> future <font color="blue">arrangement</font>s</font>; or         •  we may not be able to <font color="blue">negotiate future <font color="blue">collaborative</font> <font color="blue">arrangement</font>s</font>, or     renewals of existing <font color="blue">collaborative</font> <font color="blue">agreement</font>s, on acceptable terms</td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________    [74]Table of <font color="blue">Contents       </font>       Because  these and other <font color="blue">factors may</font> be beyond our control, the     <font color="blue">development</font> or <font color="blue">commercialization</font> of our <font color="blue">products may delayed</font> or otherwise     <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>If we or any of our <font color="blue">collaborative</font> partners terminate a <font color="blue">collaborative</font>     <font color="blue">arrangement</font>, we may be required to <font color="blue">devote <font color="blue">additional</font> resources</font> to product     <font color="blue">development</font> and <font color="blue">commercialization</font> or we may need to cancel some <font color="blue">development</font>     programs, which <font color="blue">could <font color="blue">adversely</font> affect</font> our <font color="blue">product pipeline</font> and business</td>
    </tr>
    <tr>
      <td>If our <font color="blue">direct selling efforts</font> for our <font color="blue">products fail</font>, our business expansion     plans <font color="blue">could suffer</font> and our ability to <font color="blue">generate revenue will</font> be diminished</td>
    </tr>
    <tr>
      <td>We have a <font color="blue">relatively</font> small <font color="blue"><font color="blue">sales force</font> compared</font> to our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We     intend  to expand our <font color="blue">direct <font color="blue">sales force</font></font> in the future</td>
    </tr>
    <tr>
      <td>Even if we are     successful in increasing the size of our <font color="blue">sales force</font>, it may take some     period of time before any new sales personnel become <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>If our     <font color="blue">direct <font color="blue">sales force</font></font> is not successful, we may not be able to <font color="blue">increase market</font>     awareness and sales of our products</td>
    </tr>
    <tr>
      <td>If our distributor <font color="blue"><font color="blue">relationship</font>s</font> are not successful, our ability to market     and sell our <font color="blue">products would</font> be harmed and our <font color="blue">financial performance will</font> be     <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We depend on <font color="blue"><font color="blue">relationship</font>s</font> with distributors for the marketing and     sales of our products in the industrial and <font color="blue">clinical market</font>s in various     <font color="blue">geographic regions</font> and we have a limited ability to influence their efforts</td>
    </tr>
    <tr>
      <td>Product <font color="blue">sales through distributors</font> represented 14prca and 20prca of <font color="blue">total product</font>     sales for 2005 and 2004, respectively</td>
    </tr>
    <tr>
      <td>While <font color="blue">sales through distributors</font>     accounted for a <font color="blue">smaller percentage</font> of our <font color="blue">total revenues</font> in <font color="blue">recent periods</font>     because of the increase in <font color="blue">direct sales</font> in <font color="blue">connection with</font> the BDS program,     we expect to continue to <font color="blue">rely substantially on</font> our distributor <font color="blue"><font color="blue">relationship</font>s</font>     for <font color="blue">sales into</font> other markets or <font color="blue">geographic regions</font>, which is key to our     long-term growth potential</td>
    </tr>
    <tr>
      <td>We <font color="blue">also rely on various distributors</font> for our     sales of <font color="blue">SmartCycler </font>in Europe, China, Mexico and other parts of the world</td>
    </tr>
    <tr>
      <td>Relying <font color="blue">on distributors</font> for our sales and marketing <font color="blue">could harm</font> our business     for <font color="blue">various reasons</font>, including:         •  <font color="blue">agreement</font>s with <font color="blue">distributors may</font> terminate prematurely due to     dis<font color="blue">agreement</font>s or may result in <font color="blue">litigation</font> between the partners;          •   we  may not be able to renew existing distributor <font color="blue">agreement</font>s on     acceptable terms; and         •  our <font color="blue">distributors may</font> not <font color="blue">devote sufficient resources</font> to the sale of     products;         •  our <font color="blue">distributors may</font> be <font color="blue">unsuccessful</font> in marketing our products;         •  our existing <font color="blue"><font color="blue">relationship</font>s</font> with <font color="blue">distributors may</font> preclude us from     entering into <font color="blue"><font color="blue">additional</font> future <font color="blue">arrangement</font>s</font>; and          •  we may not be able to negotiate future distributor <font color="blue">agreement</font>s on     acceptable terms</td>
    </tr>
    <tr>
      <td>We may be subject to third-party claims that we require <font color="blue"><font color="blue">additional</font> licenses</font>     for our products and we could face costly <font color="blue">litigation</font>, <font color="blue">which could</font> cause us     to pay substantial damages and limit our ability to sell some or all of our     products</td>
    </tr>
    <tr>
      <td>Our industry is <font color="blue">characterized by</font> a large number of patents, claims of     which appear to overlap in many cases</td>
    </tr>
    <tr>
      <td>As a result, there is a <font color="blue">significant</font>     amount  of  <font color="blue">uncertainty</font>  regarding the extent of <font color="blue">patent protection</font> and     <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>may have <font color="blue">pending patent</font> <font color="blue">applications</font> (which are     <font color="blue">typically confidential</font> for the <font color="blue">first eighteen months following filing</font>) that     cover <font color="blue">technologies</font> we <font color="blue">incorporate</font> in our products</td>
    </tr>
    <tr>
      <td>As a result, we may be     subjected to substantial damages for past <font color="blue">infringement</font> or be required to     modify our products or stop selling them if it is ultimately determined that     our products infringe a third party’s <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>Moreover, from     time  to time, we receive <font color="blue">correspondence</font> and other <font color="blue">communications from</font>     companies that ask us to evaluate the need for a license of patents they     hold, and indicating or suggesting that we need a license to their patents     in order to offer our products and services or to conduct our business     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, Idaho Technology, Inc</td>
    </tr>
    <tr>
      <td>and University of Utah     Research  Foundation filed a complaint <font color="blue">against us</font> in the <font color="blue">United States</font>     District Court for the District of Utah claiming that we <font color="blue">infringe certain</font>     patents; however, this complaint has not <font color="blue">yet been served on us</font></td>
    </tr>
    <tr>
      <td>If the     plaintiffs determine to pursue this action, we intend to                                         23       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font><font color="blue">vigorously defend ourselves</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation</font> related to claims of patent     <font color="blue">infringement</font> could consume our resources and lead to <font color="blue">significant</font> damages,     <font color="blue">royalty payments</font> or an <font color="blue">injunction on</font> the sale of <font color="blue">certain products</font></td>
    </tr>
    <tr>
      <td>Any     <font color="blue">additional</font>  licenses  to  patented <font color="blue">technology</font> could obligate us to pay     substantial <font color="blue">additional</font> royalties, <font color="blue">which could</font> <font color="blue">adversely</font> impact our product     costs and harm our business</td>
    </tr>
    <tr>
      <td>If we fail to maintain and protect our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>, our     <font color="blue">competitors</font> could use our <font color="blue">technology</font> to develop <font color="blue">competing products</font> and our     business will suffer</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitive</font> success will be affected in part by our continued     ability  to  obtain and maintain <font color="blue">patent protection</font> for our <font color="blue">inventions</font>,     <font color="blue">technologies</font> and <font color="blue">discoveries</font>, including our <font color="blue"><font color="blue">intellectual</font> property</font> that     includes <font color="blue">technologies</font> that we license</td>
    </tr>
    <tr>
      <td>Our ability to do so <font color="blue">will depend on</font>,     among other things, complex legal and factual questions</td>
    </tr>
    <tr>
      <td>We have patents     related to some <font color="blue">technology</font> and have licensed some of our <font color="blue">technology</font> under     patents of others</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our patents and <font color="blue">licenses will</font>     <font color="blue">successfully preclude others from using</font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">pending patent</font>     <font color="blue">applications</font> may lack priority over others’ <font color="blue">applications</font> or may not result     in  the  issuance  of  patents</td>
    </tr>
    <tr>
      <td>Even if issued, our <font color="blue">patents may</font> not be     <font color="blue">sufficiently</font> broad to provide protection against <font color="blue">competitors</font> with similar     <font color="blue">technologies</font> and may be challenged, invalidated or <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>In addition to patents, we rely on a <font color="blue">combination</font> of <font color="blue">trade secrets</font>,     copyright and trademark laws, nondisclosure <font color="blue">agreement</font>s, licenses and other     <font color="blue">contractual provisions</font> and <font color="blue">technical measures</font> to maintain and develop our     <font color="blue">competitive</font> position <font color="blue">with respect</font> to <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>Nevertheless,     these <font color="blue">measures may</font> not be adequate to safeguard the <font color="blue">technology</font> underlying     our products</td>
    </tr>
    <tr>
      <td>For example, employees, consultants and others who <font color="blue">participate</font>     in the <font color="blue">development</font> of our <font color="blue">products may breach</font> their <font color="blue">agreement</font>s with us     regarding our <font color="blue"><font color="blue">intellectual</font> property</font> and we may not have <font color="blue">adequate remedies</font>     for  the  breach</td>
    </tr>
    <tr>
      <td>We  also may not be able to <font color="blue">effective</font>ly protect our     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> in some <font color="blue">foreign countries</font>, as many countries do     not offer the same level of <font color="blue">legal protection</font> for <font color="blue"><font color="blue">intellectual</font> property</font> as     the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Furthermore, for a variety of reasons, we may decide not     to file for patent, copyright or <font color="blue">trademark protection outside</font> of the United     States</td>
    </tr>
    <tr>
      <td>Our <font color="blue">trade secrets</font> could become known through other unforeseen means</td>
    </tr>
    <tr>
      <td><font color="blue">Notwithstanding  </font>our efforts to protect our <font color="blue"><font color="blue">intellectual</font> property</font>, our     <font color="blue">competitors</font> may independently develop similar or alternative <font color="blue">technologies</font> or     products that are equal or superior to our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may     also develop similar <font color="blue">products without infringing on</font> any of our <font color="blue">intellectual</font>     <font color="blue">property rights</font> or <font color="blue">design around</font> our <font color="blue">proprietary</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Furthermore,     any efforts to enforce our <font color="blue">proprietary</font> rights could result in disputes and     legal  <font color="blue">proceedings</font>  that could be costly and divert attention from our     business</td>
    </tr>
    <tr>
      <td>We may need to <font color="blue">initiate lawsuits</font> to protect or enforce our patents, which     would be expensive and, if we lose, may cause us to lose some, if not all,     of our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>, and <font color="blue">thereby impair</font> our ability to     compete</td>
    </tr>
    <tr>
      <td>We  <font color="blue">rely on patents</font> to protect a large part of our <font color="blue">intellectual</font>     property</td>
    </tr>
    <tr>
      <td>To protect or enforce our <font color="blue">patent rights</font>, we <font color="blue">may initiate patent</font>     <font color="blue">litigation</font> against <font color="blue">third parties</font>, such as <font color="blue">infringement</font> suits or <font color="blue">interference</font>     <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">lawsuits could</font> be expensive, take <font color="blue">significant</font> time and     divert <font color="blue">management</font>’s attention from other business concerns</td>
    </tr>
    <tr>
      <td>They would also     put our <font color="blue">patents at risk</font> of being invalidated or <font color="blue">interpreted narrowly</font>, and     our patent <font color="blue">applications</font> at risk of not issuing</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also provoke</font> these     <font color="blue">third parties</font> to assert claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Patent law relating to the scope     of claims in the <font color="blue">technology</font> fields in which we operate is <font color="blue">still evolving</font>     and, consequently, patent positions in our industry are <font color="blue">generally</font> uncertain</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we would prevail in any of these suits or that the     damages or other <font color="blue">remedies awarded</font>, if any, would be <font color="blue">commercially</font> valuable</td>
    </tr>
    <tr>
      <td>During the course of these suits, there may be public <font color="blue">announcements</font> of the     results of hearings, motions and other interim <font color="blue">proceedings</font> or <font color="blue">development</font>s     in the <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Any public <font color="blue">announcements</font> related to these suits could     cause our stock price to decline</td>
    </tr>
    <tr>
      <td>Our sales cycle, <font color="blue">particularly</font> in the <font color="blue">industrial market</font> and clinical     molecular <font color="blue">diagnostic</font>s market, can be lengthy, which can cause <font color="blue">variability</font>     and <font color="blue">unpredictability</font> in our operating results</td>
    </tr>
    <tr>
      <td>The <font color="blue">sales cycles</font> for our products, <font color="blue">particularly</font> in the industrial     market and the clinical molecular <font color="blue">diagnostic</font>s market, can be lengthy, which     makes it more <font color="blue">difficult</font> for us to <font color="blue">accurately forecast revenues</font> in a given     period, and may cause revenues and operating results to vary <font color="blue">significant</font>ly     from period to period</td>
    </tr>
    <tr>
      <td>Sales of                                         24       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font>our products to the <font color="blue">industrial market</font> often involve purchasing decisions by     large public and <font color="blue">private institutions</font>, and any purchases can require many     levels of pre-approval</td>
    </tr>
    <tr>
      <td>In addition, many of these <font color="blue">sales depend on</font> these     institutions receiving research grants from various federal agencies, which     <font color="blue">grants vary considerably from year</font> to year in <font color="blue">both amount</font> and timing due to     the <font color="blue">political process</font></td>
    </tr>
    <tr>
      <td>As a result, we may expend considerable resources on     <font color="blue">unsuccessful</font> <font color="blue">sales efforts</font> or we may not be able to complete <font color="blue">transactions</font> on     the schedule anticipated</td>
    </tr>
    <tr>
      <td>Our international <font color="blue">operations</font> subject us to <font color="blue">additional</font> risks and costs</td>
    </tr>
    <tr>
      <td>Our international <font color="blue">operations</font> are subject to a number of <font color="blue"><font color="blue">difficult</font>ies</font>     and <font color="blue">special costs</font>, including:         •  compliance with multiple, conflicting and changing <font color="blue">government</font>al laws     and <font color="blue">regulations</font>;         •  laws and business practices favoring local <font color="blue">competitors</font>;         •  potential for exchange and <font color="blue">currency risks</font>;         •  potential <font color="blue">difficult</font>y in <font color="blue">collecting accounts receivable</font>;         •  import and <font color="blue">export restrictions</font> and tariffs;         •  <font color="blue"><font color="blue">difficult</font>ies</font> staffing and managing foreign <font color="blue">operations</font>;         •  <font color="blue"><font color="blue">difficult</font>ies</font> and expense in enforcing <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>;         •  business risks, including <font color="blue">fluctuations</font> in demand for our products and     the cost and effort to conduct international <font color="blue">operations</font> and <font color="blue">travel abroad</font> to     promote international <font color="blue">distribution</font>, and <font color="blue">global economic conditions</font>;         •  <font color="blue">multiple conflicting tax laws</font> and <font color="blue">regulations</font>; and         •  political and <font color="blue">economic instability</font></td>
    </tr>
    <tr>
      <td>We intend to expand our <font color="blue">international sales</font> and <font color="blue">marketing <font color="blue">activities</font></font>,     including through our European subsidiary, and <font color="blue">enter into</font> <font color="blue"><font color="blue">relationship</font>s</font> with     <font color="blue">additional</font>  international <font color="blue">distribution</font> partners</td>
    </tr>
    <tr>
      <td>We may not be able to     attract international <font color="blue">distribution</font> partners that will be able to market our     products <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>Our international <font color="blue">operations</font> could also increase our     exposure to <font color="blue">international laws</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot <font color="blue">comply with</font></font>     foreign  laws  and <font color="blue">regulations</font>, which are <font color="blue">often complex</font> and subject to     variation  and unexpected changes, we <font color="blue">could incur</font> unexpected costs and     potential <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>For example, the <font color="blue">government</font>s of <font color="blue">foreign countries</font>     <font color="blue">might attempt</font> to regulate our products and services or levy sales or other     taxes relating to our <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">foreign countries</font> may impose     tariffs, duties, price controls or other <font color="blue">restrictions on foreign currencies</font>     or <font color="blue">trade barriers</font>, any of <font color="blue">which could</font> make it more <font color="blue">difficult</font> for us to     conduct our business</td>
    </tr>
    <tr>
      <td>The nature of some of our <font color="blue">products may also</font> subject us to export     <font color="blue">control <font color="blue">regulation by</font></font> the <font color="blue">US Department of State and the Department </font>of     Commerce</td>
    </tr>
    <tr>
      <td><font color="blue">Violations </font>of these <font color="blue">regulations</font> can result in monetary penalties     and denial of export privileges</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">SmartCycler </font> and <font color="blue">GeneXpert </font><font color="blue">products will</font> be <font color="blue">distributed</font> in     <font color="blue">throughout</font>  Europe  under  the CE IVD mark, and we intend to introduce     <font color="blue">additional</font> products under the CE IVD mark as we pursue our expansion plans</td>
    </tr>
    <tr>
      <td>Our use of the CE IVD mark is <font color="blue">based on self declarations</font> of <font color="blue">conformity with</font>     stated <font color="blue">directives</font> and standards of the <font color="blue">European Parliament and Council </font>and     is  subject to review by competent <font color="blue">authorities</font> in Europe</td>
    </tr>
    <tr>
      <td>To date, our     products  and  use  of self-declarations have not <font color="blue">been reviewed by</font> any     <font color="blue">competent authority</font></td>
    </tr>
    <tr>
      <td>If our products are reviewed, a <font color="blue">competent authority</font> may     find that our products do not <font color="blue">comply with</font> stated <font color="blue">directives</font> and standards</td>
    </tr>
    <tr>
      <td>Any finding of non-conformity could prevent or otherwise <font color="blue">adversely</font> affect     our  ability  to  distribute  products  in  Europe and result in other     <font color="blue">consequences</font>, including both criminal sanctions, such as the imposition of     fines or penalties, and civil claims for <font color="blue">damages from persons suffering</font>     <font color="blue">damage as</font> a result of the non-conformity</td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly dependent on</font> the <font color="blue">principal members</font> of our <font color="blue">management</font> and     scientific  staff</td>
    </tr>
    <tr>
      <td>The loss of services of any of these <font color="blue">persons could</font>     <font color="blue">seriously harm</font> our product <font color="blue">development</font> and <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>In     addition, we will require <font color="blue">additional</font> skilled personnel in <font color="blue">areas such as</font>     microbiology, clinical and sales and marketing</td>
    </tr>
    <tr>
      <td>Attracting, retaining and     <font color="blue">training personnel with</font> the <font color="blue">requisite skills remains challenging</font>, and, as     <font color="blue">general economic conditions improve</font>, is becoming increasingly <font color="blue">competitive</font>,     <font color="blue">particularly</font> in the <font color="blue">Silicon Valley </font>area of <font color="blue">California </font>where our main office     is  located</td>
    </tr>
    <tr>
      <td>If at any point we are unable to hire, train and retain a     sufficient number of <font color="blue">qualified employees</font> to match our growth, our ability to     conduct and expand our business could be <font color="blue">seriously reduced</font></td>
    </tr>
    <tr>
      <td>If we become subject to claims relating to improper handling, storage or     disposal of <font color="blue">hazardous materials</font>, we <font color="blue">could incur</font> <font color="blue">significant</font> cost and time to     comply</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> processes involve the <font color="blue">controlled storage</font>,     use and disposal of <font color="blue">hazardous materials</font>, including <font color="blue">biological hazardous</font>     materials</td>
    </tr>
    <tr>
      <td>We are subject to federal, state and local <font color="blue">regulations</font> governing     the use, <font color="blue">manufacture</font>, storage, handling and disposal of materials and waste     products</td>
    </tr>
    <tr>
      <td>We may incur <font color="blue">significant</font> costs complying with both existing and     <font color="blue">future <font color="blue">environmental laws</font></font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>In particular, we are subject to     <font color="blue">regulation by</font> the Occupational Safety and Health Administration (OSHA) and     the Environmental Protection Agency (EPA), and to <font color="blue">regulation under</font> the Toxic     Substances Control Act and the Resource Conservation and Recovery Act</td>
    </tr>
    <tr>
      <td>OSHA     or  the  EPA  may  adopt  <font color="blue">regulations</font> that may affect our research and     <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>We are unable to <font color="blue">predict whether</font> any <font color="blue">agency will adopt</font>     any <font color="blue">regulations</font> that would have a material adverse effect on our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The  risk  of <font color="blue"><font color="blue">accident</font>al contamination</font> or <font color="blue">injury from hazardous</font>     <font color="blue">materials cannot</font> be <font color="blue">eliminated completely</font></td>
    </tr>
    <tr>
      <td>In the event of an <font color="blue">accident</font>, we     could be held liable for any damages that result, and any <font color="blue">liability</font> could     exceed the limits or <font color="blue">fall outside</font> the coverage of our insurance</td>
    </tr>
    <tr>
      <td>We may not     be able to maintain <font color="blue">insurance on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>We could be     required  to  incur <font color="blue">significant</font> costs to <font color="blue">comply with</font> current or future     <font color="blue">environmental laws</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Changes in the <font color="blue">accounting treatment</font> of <font color="blue">stock options will <font color="blue">adversely</font> affect</font>     our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">In December </font>2004, the <font color="blue">Financial Accounting Standard Board </font>issued a new     statement, which requires all share-based payments to employees, including     grants  of  <font color="blue">employee stock options</font>, to be recognized as expense in the     <font color="blue">financial statements based on</font> their <font color="blue">fair values</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">new rules will</font> be     <font color="blue">effective</font> for us January 1, 2006</td>
    </tr>
    <tr>
      <td>This change will <font color="blue">materially</font> and <font color="blue">adversely</font>     affect our reported results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If a <font color="blue">catastrophe</font> strikes our <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font>, we may be unable to     <font color="blue">manufacture</font> our products for a substantial amount of time and we would     experience <font color="blue">lost revenue</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font> are located in Sunnyvale, California</td>
    </tr>
    <tr>
      <td>Although we have business <font color="blue">interruption insurance</font>, our <font color="blue">facilities</font> and some     pieces of <font color="blue">manufacturing</font> equipment are <font color="blue">difficult</font> to replace and could require     substantial replacement lead-time</td>
    </tr>
    <tr>
      <td>Various types of <font color="blue">disasters</font>, including     <font color="blue">earthquakes</font>,  fires,  floods  and  acts  of  terrorism, may affect our     <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Earthquakes </font>are of <font color="blue">particular significance since</font>     the <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font> are located in an earthquake-prone area</td>
    </tr>
    <tr>
      <td>In the     event our existing <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font> or equipment is <font color="blue">affected by</font>     man-made or natural <font color="blue">disasters</font>, we may be unable to <font color="blue">manufacture</font> products for     sale, meet customer demands or sales <font color="blue">projections</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">manufacturing</font>     <font color="blue">operations</font> were curtailed or ceased, it would <font color="blue">seriously harm</font> our business</td>
    </tr>
    <tr>
      <td>We might require <font color="blue">additional</font> capital to support business growth, and such     <font color="blue">capital might</font> not be available</td>
    </tr>
    <tr>
      <td>We intend to continue to make <font color="blue"><font color="blue">investment</font>s</font> to support business growth     and may require <font color="blue">additional</font> funds to respond to business challenges, which     include the need to develop <font color="blue">new products</font> or <font color="blue">enhance existing products</font>,     conduct <font color="blue">clinical trials</font>, enhance our operating <font color="blue">infrastructure</font> and acquire     <font color="blue">complementary</font>  <font color="blue">businesses</font> and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Equity and debt financing,     however, might not be available when needed or, if available,                                         26       _________________________________________________________________    [78]Table of <font color="blue">Contents       </font>might not be <font color="blue">available on terms</font> satisfactory to us</td>
    </tr>
    <tr>
      <td>In addition, to the     extent that <font color="blue">additional</font> capital is <font color="blue">raised through</font> the sale of equity or     <font color="blue">convertible debt securities</font>, the issuance of these <font color="blue">securities could</font> result     in dilution to our <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>In addition, these <font color="blue">securities may</font> be sold     at a <font color="blue">discount from</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font>, and may include     right <font color="blue">preferences</font> or <font color="blue">privileges senior</font> to those of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we     are unable to obtain <font color="blue">adequate financing</font> or <font color="blue">financing on terms</font> satisfactory     to us, our ability to continue to support our business growth and to respond     to business <font color="blue">challenges could</font> be <font color="blue">significant</font>ly limited</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with <font color="blue">regulations</font> governing public company <font color="blue">corporate governance</font>     and reporting is complex and expensive</td>
    </tr>
    <tr>
      <td>Many laws and <font color="blue">regulations</font>, notably those adopted in <font color="blue">connection with</font>     the Sarbanes-Oxley Act of 2002 by the SEC and the NASDAQ National Market,     impose obligations on public companies, such as ours, which have increased     the scope, complexity, and cost of <font color="blue">corporate governance</font>, reporting, and     <font color="blue">disclosure practices</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">implementation</font> of these reforms and <font color="blue">enhanced new</font>     <font color="blue">disclosures necessitates</font> substantial <font color="blue">management</font> time and oversight and     requires us to incur <font color="blue">significant</font> <font color="blue">additional</font> accounting and <font color="blue">legal costs</font></td>
    </tr>
  </tbody>
</table>